MCM
MDCO

Matarin Capital Management’s Medicines Co MDCO Stock Holding History

Matarin Capital Management’s Portfolio MDCO Stock Details MDCO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-6,274
Closed -$193K – 223
2013
Q2 		$193K Buy
+6,274
New +$210K 0.19% 161

Other funds holding MDCO

SAC
Smith Affiliated Capital New York $86.5B AUM 5.91% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Matarin Capital Management's MDCO Position: Q3 2013 in Review

Matarin Capital Management sold out of Medicines Co (MDCO) in Q3 2013, closing a stake of 6,274 shares — an estimated $193K sold.

Matarin Capital Management first reported a position in MDCO in Q2 2013 and held it in 1 quarter. The position peaked at $193K in Q2 2013. 172 funds tracked by Wall St. Rank hold MDCO as of Q3 2013.

  • Matarin Capital Management reported no remaining Medicines Co position as of Q3 2013 after selling out during the quarter.
  • Matarin Capital Management sold 6,274 Medicines Co shares in Q3 2013, an estimated $193K.
  • Matarin Capital Management first reported a position in Medicines Co in Q2 2013 and held it in 1 quarter.
  • Matarin Capital Management's Medicines Co position peaked at $193K in Q2 2013.
  • 172 funds tracked by Wall St. Rank held Medicines Co as of Q3 2013.

Based on Matarin Capital Management's 13F filing for Q3 2013, filed 30 Oct 2013.